{
  "id": "5167d47e298dcd4e5100005e",
  "type": "summary",
  "question": "What is the use of MammaPrint and Oncotype DX?",
  "ideal_answer": "The MammaPrint and Oncotype DX assays are used to predict breast cancer recurrence risk and guide adjuvant chemotherapy decisions.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23573359",
    "http://www.ncbi.nlm.nih.gov/pubmed/23411384",
    "http://www.ncbi.nlm.nih.gov/pubmed/19101988",
    "http://www.ncbi.nlm.nih.gov/pubmed/19585214",
    "http://www.ncbi.nlm.nih.gov/pubmed/21998967",
    "http://www.ncbi.nlm.nih.gov/pubmed/20587405",
    "http://www.ncbi.nlm.nih.gov/pubmed/21479927",
    "http://www.ncbi.nlm.nih.gov/pubmed/22359236",
    "http://www.ncbi.nlm.nih.gov/pubmed/23495982",
    "http://www.ncbi.nlm.nih.gov/pubmed/23462680",
    "http://www.ncbi.nlm.nih.gov/pubmed/21501481",
    "http://www.ncbi.nlm.nih.gov/pubmed/23337633"
  ],
  "snippets": [
    {
      "text": "Molecular tests such as the 21 gene expression test (Oncotype DX(TM)) and 70 gene microarray test (MammaPrint(\u00ae)) have revolutionized the predictive and prognostic tools in the clinic. By stratifying the risk of recurrence for patients, the tests are able to provide clinicians with more information on the treatment outcomes of using chemotherapy, HER2 targeted therapy or endocrine therapy or the combination of the therapies for patients with particular genetic expressions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23573359",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Gene expression profiling tests are used in an attempt to determine the right treatment for the right person with early-stage breast cancer that may have spread to nearby lymph nodes but not to distant parts of the body. These new diagnostic approaches are designed to spare people who do not need additional treatment (adjuvant therapy) the side effects of unnecessary treatment, and allow people who may benefit from adjuvant therapy to receive it. In the present review we discuss in detail the major diagnostic tests available such as MammaPrint dx, Oncotype dx, PAM50, Mammostrat, IHC4, MapQuant DX, Theros-Breast Cancer Gene Expression Ratio Assay, and their potential clinical applications.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23462680",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Oncotype DX, PAM50, and MammaPrint are multigene tests that are being used clinically for early-stage breast cancer to predict recurrence risk and guide adjuvant chemotherapy decisions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23411384",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "We critically evaluated the available evidence on genomic tests in breast cancer to define their prognostic ability and likelihood to determine treatment benefit. METHODS: Independent evaluation of six genomic tests [Oncotype Dx\u2122, MammaPrint(\u00ae), Genomic Grade Index, PAM50 (ROR-S), Breast Cancer Index, and EndoPredict] was carried out by a panel of experts in three parameters: analytical validity, clinical validity, and clinical utility based on the principles of the EGAPP criteria. PANEL",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23337633",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Gene expression profiling (GEP) is being used increasingly for risk stratification to identify women with lymph node-negative, estrogen receptor-positive, early stage breast cancer who are most likely to benefit from adjuvant chemotherapy. The authors of this report evaluated the cost effectiveness of recurrence score-guided treatment using 2 commercially available GEP tests, Oncotype DX (Genomic Health, Redwood City, Calif) and MammaPrint (Agendia Inc., Irvine, Calif), from a third-party payer's perspective.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22359236",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "genomic tumor signatures that predict a patient's risk of breast cancer recurrence and response to chemotherapy. The paper builds on empirical evidence from the two trials to explore the emergence of diverse regulatory-scientific hybrids; that is, the paper discusses configurations of genomic practice and bioclinical work that depend on linkages between technical, commercial, patient, clinical, and legal interests and institutions. The development of the genomic signatures for each trial--Oncotype DX and MammaPrint--has followed quite different routes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21998967",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Real-time RT-PCR confirmed the 5-gene prognostic signature that was distinct from an FDA-cleared 70-gene signature of MammaPrint panel and from the Oncotype DX recurrence score assay panel. These data suggest that neoadjuvant immunotherapy in patients with high risk of relapse may reduce tumor recurrence by inducing the immune function genes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479927",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "We will review the primary tools in clinical use: Adjuvant!, Oncotype DX, and MammaPrint as well as intrinsic subtypes and the plans for their further assessment in the clinical trial setting. The expected benefit from these models are that treatment recommendations for women with early-stage breast cancer will become more individualized and thereby appropriate by combining standard clinicopathologic and molecular features.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20587405",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "newer prognostic markers with a focus on the 21-gene recurrence score (Oncotype DX(\u2122)), 70-gene prognosis profile (Mammaprint(\u00ae)), and Adjuvant! Online. Conclusion: These techniques differ in their execution and application and have been demonstrated to provide further data on risk stratification as compared with conventional breast-cancer-risk factors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23495982",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "diagnostic tools such as MammaPrint and oncotype-DX are beginning to have impact on clinical practice of breast cancer. They are based on gene expression profiling, i.e., gene expression analysis of a large number of genes. Their unique characteristic is the use of a score calculated from expression values of a number of genes, for which the Food and Drug Administration (FDA) created a new diagnostic category entitled \"in vitro diagnostic multivariate index assay (IVDMIA).\"",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19585214",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "the gene expression signatures that define specific prognostic subtypes in other breast cancer datasets, such as luminal A and B, basal, normal-like, and ERBB2+, and prognostic signatures including MammaPrint and Oncotype DX, predicted genomic instability in our samples.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19101988",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045506"
  ]
}